Drug Approval | January 21, 2022
US FDA approves Idorsia’s insomnia drug
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
